At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Duloxetinedrug
Likely dose
Duloxetine 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
In Brief
A Phase 4 clinical trial evaluating Duloxetine for Panic Disorder. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether duloxetine is effective in the treatment of panic disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPanic Disorder
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedFeb 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedFeb 22, 2007
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.4 years ago
Interventions
Duloxetinedrug
Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.